[1]高忠爱,杨波,郑妙艳,等.糖尿病合并大量蛋白尿的中西医治疗策略[J].国际内分泌代谢杂志,2021,41(06):583-586.[doi:10.3760/cma.j.cn121383-20210930-09088]
　Gao Zhongai,Yang Bo,Zheng Miaoyan,et al.Treatment strategies of traditional Chinese and western medicine in diabetic patients with overt proteinuria[J].International Journal of Endocrinology and Metabolism,2021,41(06):583-586.[doi:10.3760/cma.j.cn121383-20210930-09088]
点击复制

糖尿病合并大量蛋白尿的中西医治疗策略()
分享到：

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
41
期数:
2021年06期
页码:
583-586
栏目:
专家论坛
出版日期:
2021-12-20

文章信息/Info

Title:
Treatment strategies of traditional Chinese and western medicine in diabetic patients with overt proteinuria
作者:
高忠爱1; 杨波2; 郑妙艳1; 贾俊亚3; 常宝成1
1天津医科大学朱宪彝纪念医院、天津市内分泌研究所、国家卫生健康委员会激素与发育重点实验室、天津市代谢性疾病重点实验室 300134; 2天津中医药大学第一附属医院 300192; 3天津医科大学总医院 300052
Author(s):
Gao Zhongai1;  Yang Bo2;  Zheng Miaoyan1;  Jia Junya3;  Chang Baocheng1.
1NHC Key Laboratory of Hormones and Development, Tianjin Key Laboratory of Metabolic Diseases, Chu Hsien-I Memorial Hospital & Tianjin Institute of Endocrinology, Tianjin Medical University, Tianjin 300134, China; 2First Teaching
关键词:
糖尿病肾脏病;  大量蛋白尿;  中西医;  治疗
Keywords:
Diabetic kidney disease;  Overt proteinuria;  Traditional Chinese and western medicine;  Treatment
DOI:
10.3760/cma.j.cn121383-20210930-09088
摘要:
糖尿病肾脏病(DKD)是2型糖尿病严重的微血管并发症,已成为导致终末期肾病的首要病因。DKD患者一旦进展到大量蛋白尿阶段,疾病已不可逆转,预后较差。而合理规范的治疗可降低尿蛋白,延缓肾病进展。目前一些新型降糖药能减少DKD患者尿蛋白,尤其是钠-葡萄糖协同转运蛋白2抑制剂,能降低DKD患者肾脏复合终点风险; 中医中药在延缓DKD合并大量蛋白尿患者肾功能恶化、改善临床症候方面有一定的优势。本文将根据国内外相关研究报道以及自身的临床体会对糖尿病合并大量蛋白尿的中西医治疗策略进行讨论。
Abstract:
Diabetic kidney disease(DKD)is a serious microvascular complication of type 2 diabetes mellitus, and it has become the major cause of end-stage renal disease. Once DKD progresses to overt proteinuria, it is irreversible and the prognosis is poor. Reasonable and standardized treatment can reduce urinary protein and delay the progression of the disease. At present, some new hypoglycemic drugs can reduce urine protein, especially sodium-glucose cotransporter 2 inhibitors, which can reduce the risk of renal composite endpoint in patients with DKD; Traditional Chinese medicine has an advantage in delaying the deterioration of renal function and and improving clinical symptoms in patients with DKD. This paper will discuss potential treatment strategies of traditional Chinese and western medicine in diabetic patients with overt proteinuria based on relevant research and our own clinical experience.

参考文献/References:

[1] Cheng HT,Xu X,Lim PS,et al.Worldwide epidemiology of diabetes-related end-stage renal disease,2000-2015[J].Diabetes care,2021,44(1):89-97.DOI:10.2337/dc20-1913.
[2] 许杰,杨菊红,单春艳,等.住院2型糖尿病患者合并慢性肾脏病的患病率及其危险因素分析[J].中华内分泌代谢杂志,2014,30(7):597-600.DOI:10.3760/cma.j.issn.1000-6699.2014.07.014.
[3] 中华医学会肾脏病学分会专家组.糖尿病肾脏疾病临床诊疗中国指南[J].中华肾脏病杂志,2021,37(03):255-304.DOI:10.3760/cma.j.cn441217-20201125-00041.
[4] Bakris GL,Agarwal R,Anker SD,et al.Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes [J].N Engl J Med,2020,383(23):2219-2229.DOI:10.1056/NEJMoa2025845.
[5] Cherney DZI,Zinman B,Inzucchi SE,et al.Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease:an exploratory analysis from the EMPA-REG OUTCOME randomised,placebo-controlled trial [J].Lancet Diabetes Endocrinol,2017,5(8):610-621.DOI:10.1016/S2213-8587(17)30182-1.
[6] Heerspink HJL,Stefánsson BV,Correa-rotter R,et al.Dapagliflozin in patients with chronic kidney disease [J].N Engl J Med,2020,383(15):1436-1446.DOI:10.1056/NEJMoa2024816.
[7] Perkovic V,Jardine MJ,Neal B,et al.Canagliflozin and renal outcomes in type 2 diabetes and nephropathy [J].N Engl J Med,2019,380(24):2295-2306.DOI:10.1056/NEJMoa1811744.
[8] Mann JFE,Ørsted DD,Brown-Frandsen K,et al.Liraglutide and renal outcomes in type 2 diabetes [J].N Engl J Med,2017,377(9):839-848.DOI:10.1056/NEJMoa1616011.
[9] Gerstein HC,Colhoun HM,Dagenais GR,et al.Dulaglutide and renal outcomes in type 2 diabetes:an exploratory analysis of the REWIND randomised,placebo-controlled trial [J].Lancet,2019,394(10193):131-138.DOI:10.1016/S0140-6736(19)31150-X.
[10] Perez-Gomez MV,Sanchez-Niño MD,Sanz AB,et al.Horizon 2020 in diabetic kidney disease:the clinical trial pipeline for add-on therapies on top of renin angiotensin system blockade [J].J Clin Med,2015,4(6):1325-1347.DOI:10.3390/jcm4061325.
[11] Leikin JB.Venous thromboembolism prophylaxis using the Caprini score [J].Dis Mon,2019,65(8):248.DOI:10.1016/j.disamonth.2018.12.004.
[12] 王军涛.雷公藤多苷片治疗糖尿病肾病大量蛋白尿的疗效观察[J].中国继续医学教育,2015,7(24):184-185.DOI:10.3969/j.issn.1674-9308.2015.24.130.
[13] Ru Y,Luo Y,Zhou Y,et al.Adverse events associated with treatment of Tripterygium wilfordii Hook F:a quantitative evidence synthesis [J].Front Pharmacol,2019,10:1250.DOI:10.3389/fphar.2019.01250.
[14] 李旻瑶.火把花根片治疗糖尿病肾病大量蛋白尿70例临床疗效观察[J].中国医院药学杂志,2014,34(20):1762-1764.DOI:10.13286/j.cnki.chinhosppharmacyj.2014.20.17.
[15] 孟宪杰,张侃,时洪娟,等.黄葵胶囊治疗糖尿病肾病的研究概况[J].江苏中医药,2017,49(11):81-85.DOI:10.3969/j.issn.1672-397X.2017.11.032.
[16] 甘文渊.肾炎康复片治疗糖尿病肾病的Meta分析及系统评价[J].时珍国医国药,2018,29(4):1014-1016.DOI:10.3969/j.issn.1008-0805.2018.04.088.

相似文献/References:

[1]中华医学会糖尿病学分会微血管并发症学组.中国糖尿病肾脏病防治指南(2021年版)[J].国际内分泌代谢杂志,2021,41(04):388.[doi:10.3760/cma.j.cn121383-20210825-08064]
　Microvascular Complications Group of Chinese Diabetes Society.Clinical guideline for the prevention and treatment of diabetic kidney disease in China(2021 edition)[J].International Journal of Endocrinology and Metabolism,2021,41(06):388.[doi:10.3760/cma.j.cn121383-20210825-08064]
[2]谷巍,宋光耀,李晓龙.肾脏异位脂质沉积与糖尿病肾脏病脂毒性机制的研究进展[J].国际内分泌代谢杂志,2022,42(03):199.[doi:10.3760/cma.j.cn121383-20210324-03067]
　Gu Wei,Song Guangyao,Li Xiaolong..Research progress of renal ectopic lipid deposition and the mechanism of lipid toxicity in diabetic kidney disease[J].International Journal of Endocrinology and Metabolism,2022,42(06):199.[doi:10.3760/cma.j.cn121383-20210324-03067]
[3]黄婧荷,宋焱,郭立新.糖尿病肾脏病的磁共振成像评估方法及进展[J].国际内分泌代谢杂志,2023,43(04):309.[doi:10.3760/cma.j.cn121383-20220403-04007]
　Huang Jinghe,Song Yan,Guo Lixin.Magnetic resonance imaging in diabetic kidney disease:assessment and update[J].International Journal of Endocrinology and Metabolism,2023,43(06):309.[doi:10.3760/cma.j.cn121383-20220403-04007]

备注/Memo

备注/Memo:
基金项目:国家重点研发计划(2018YFC1314000); 国家自然科学基金项目(81774043,82074253); 天津市科技计划项目(17ZXMFSY00140)
通信作者:郑妙艳,Email: myzheng73@163.com; 常宝成,Email: changbc1970@126.com
更新日期/Last Update: 2021-12-10